Sun Pharma, Lupin and Torrent will continue to rally: Apurva Sheth, Samco Securities
"Bank Nifty will sustain its bullish momentum. The banking index on the weekly timeframe has witnessed a bullish breakout above its horizontal trend line, which is placed at 41,800 levels. "
Sun Pharma, Lupin and Torrent will continue to rally: Apurva Sheth, Samco Securities
"Bank Nifty will sustain its bullish momentum. The banking index on the weekly timeframe has witnessed a bullish breakout above its horizontal trend line, which is placed at 41,800 levels. "
Buy Torrent Pharmaceuticals; target of Rs 1820: Sharekhan
Sharekhan is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1820 in its research report dated October 25, 2022.
Buy Torrent Pharmaceuticals; target of Rs 1850: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1850 in its research report dated October 25, 2022.
Torrent Pharmaceuticals Ltd., incorporated in the year 1972, is a Large Cap company (having a market cap of Rs 53383.00 Crore) operating in Pharmaceuticals sector.
Torrent Pharma Q2 net profit declines to Rs 312 crore
Revenue from operations rose to Rs 2,291 crore in the July-September quarter as against Rs 2,137 crore in the year-ago period, Torrent Pharma said in a statement.
Focus on autos, capital goods and financials now: Sandip Sabharwal
"Risk averseness will remain in the market for some time and to that extent, pharma is the only sector which did not perform as well in the overall up move. So to that extent, the ownership also and some of the companies have been giving decent numbers. Largecap pharma could actually outperform and that is something which should be the trade for a few weeks. "
Buy Torrent Pharmaceuticals; target of Rs 1730: ICICI Direct
ICICI Direct is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1730 in its research report dated September 28, 2022.
Buy Torrent Pharmaceuticals; target of Rs 1724: Anand Rathi
Anand Rathi is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1724 in its research report dated September 28, 2022.
Buy Torrent Pharmaceuticals; target of Rs 1730: Sharekhan
Sharekhan is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1730 in its research report dated September 28, 2022.
Hot stocks: Brokerages maintain ‘overweight’ rating on DLF, Prestige Estates; KIMS, Torrent Pharma get ‘buy’
The residential cycle has turned positive. Market fundamentals continue to be anchored around high affordability and market share continues to gravitate towards listed developers.
Torrent Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue and Export Incentives for the year ending 31-Mar-2022.
Buy Torrent Pharmaceuticals; target of Rs 1850: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1850 in its research report dated September 28, 2022.
Brokerages give thumbs down for Torrent Pharma’s Curatio acquisition, stock tanks 6%
The domestic pharmaceutical player announced its acquisition of Curatio Healthcare for Rs 2,000 crore to strengthen its presence in the dermatology segment. It has entered into a definitive agreement to acquire 100 per cent stake, the company said in an exchange filing.
For the quarter ended June 30, 2022, the company has reported a consolidated total income of Rs 2377 crore, up 8.69 per cent from last quarter total income of Rs 2187 crore and up 9.34 per cent from last year same quarter total income of Rs 2174 crore.
Samir Mehta on how Torrent's pharma, energy & gas businesses & more
“We believe Torrent Pharma is amongst the best in class with margin at the current level and business would continue to grow in terms of double digit revenue growth and that itself would generate a momentum which would improve the margin further. On the other hand, our last seven-eight years growth has been substantially driven through the acquisitions that we made.”
Samir Mehta on how Torrent's pharma, energy & gas businesses are faring & more
“We believe Torrent Pharma is amongst the best in class with margin at the current level and business would continue to grow in terms of double digit revenue growth and that itself would generate a momentum which would improve the margin further. On the other hand, our last seven-eight years growth has been substantially driven through the acquisitions that we made.”
Samir Gupta on how Torrent's pharma, energy & gas businesses are faring & more
“We believe Torrent Pharma is amongst the best in class with margin at the current level and business would continue to grow in terms of double digit revenue growth and that itself would generate a momentum which would improve the margin further. On the other hand, our last seven-eight years growth has been substantially driven through the acquisitions that we made.”
Samir Gupta on how pharma, energy & gas businesses are faring & more
“We believe Torrent Pharma is amongst the best in class with margin at the current level and business would continue to grow in terms of double digit revenue growth and that itself would generate a momentum which would improve the margin further. On the other hand, our last seven-eight years growth has been substantially driven through the acquisitions that we made.”
Samir Gupta on how pharma, energy & gas businesses are faring & more
“We believe Torrent Pharma is amongst the best in class with margin at the current level and business would continue to grow in terms of double digit revenue growth and that itself would generate a momentum which would improve the margin further. On the other hand, our last seven-eight years growth has been substantially driven through the acquisitions that we made.”
Infra can be a good bet; not gung ho on diagnostics: Sandip Sabharwal
“Initially we are completely defying all global trends but let us see how long that lasts because it is very tough. The kind of moves Indian markets are giving are in complete contrast to emerging markets as well as world markets. The probability of that historically would not be more than 5%. Whether this 5% carries on is what we need to see.”
Cipla, JB Chemicals, Torrent lead Rs 4,500-crore race for Medley Pharma
Set up in 1969 by Sami Khatib as Medley Laboratories, the Mumbai-based privately held company, now called Medley Pharmaceuticals, ranks among the top 40 pharmaceutical companies in India, as per research firm ORG IMS.
Cipla, JB Chemicals, Torrent lead Rs 4,500-crore race for Medley Pharma
Set up in 1969 by Sami Khatib as Medley Laboratories, the Mumbai-based privately held company, now called Medley Pharmaceuticals, ranks among the top 40 pharmaceutical companies in India, as per research firm ORG IMS.
The transaction will see the exit of existing investors of Curatio, such as ChrysCapital (which holds a 20% stake) and Sequoia Capital (33%). Promoters, including GK Ramani, and the management will also be exiting the company.
During his tenure with Torrent Power, he has worked across different business segments of the company – namely Renewables, Thermal Generation and Distribution.
Buy Torrent Pharmaceuticals; target of Rs 1820: Sharekhan
Sharekhan is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1820 in its research report dated July 29, 2022.